Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0C7KK
|
|||
| Former ID |
DCL000283
|
|||
| Drug Name |
Zenarestat
|
|||
| Synonyms |
112733-06-9; FR-74366; FK-366; Zenarestat [USAN:INN]; Zenarestatum [INN-Latin]; FR 74366; UNII-180C9PJ8JT; FK 366; [3-(4-bromo-2-fluorobenzyl)-7-chloro-2,4-dioxo-3,4-dihydroquinazolin-1(2h)-yl]acetic acid; CI-1014; CI 1014; CHEMBL10413; 180C9PJ8JT; 2-(7-Chloro-3-(4-bromo-2-fluorobenzyl)-1,2,3,4-tetrahydro-2,4-dioxoquinazolin)-1-acetic acid; Zenarestatum; DSSTox_RID_82249; 3-(4-Bromo-2-fluorobenzyl)-7-chloro-3,4-dihydro-2,4-dioxo-1(2H)-quinazolineacetic acid; DSSTox_CID_27296; ZES; FR74366; Fk366; Zenarestat (USAN/INN); [3-(4-BROMO-2-FLUORO-BENZYL)-7-CHLORO-2,4-DIOXO-3,4-DIHYDRO-2H-QUINAZOLIN-1-YL]-ACETIC ACID; (3-(4-bromo-2-fluorobenzyl)-7-chloro-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-1-yl)acetic acid; 2-[3-[(4-bromo-2-fluorophenyl)methyl]-7-chloro-2,4-dioxoquinazolin-1-yl]acetic acid; 3-((4-Bromo-2-fluorophenyl)methyl)-7-chloro-3,4-dihydro-2,4-dioxo-1(2H)-quinazolineaceticacid
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Diabetic neuropathy [ICD-11: 8C0Z; ICD-10: G63, G63.2] | Terminated | [1], [2] | |
| Company |
Ono Pharmaceutical; Fujisawa Pharmaceutical
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C17H11BrClFN2O4
|
|||
| Canonical SMILES |
C1=CC2=C(C=C1Cl)N(C(=O)N(C2=O)CC3=C(C=C(C=C3)Br)F)CC(=O)O
|
|||
| InChI |
1S/C17H11BrClFN2O4/c18-10-2-1-9(13(20)5-10)7-22-16(25)12-4-3-11(19)6-14(12)21(17(22)26)8-15(23)24/h1-6H,7-8H2,(H,23,24)
|
|||
| InChIKey |
SXONDGSPUVNZLO-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 112733-06-9
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
822640, 5366122, 7891218, 8153507, 12014058, 14759400, 17397895, 29224761, 46507491, 46516730, 50040925, 50184937, 57322915, 103064709, 103085748, 103170569, 104310073, 117389120, 124954386, 126591590, 129303239, 134338939, 134340696, 135024687, 137183403, 142347545, 144210777, 160965347, 162311567, 163306697, 170466650, 178103990, 179149602, 184526342, 198947648, 224890862, 226432807
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Aldose reductase (AKR1B1) | Target Info | Inhibitor | [3] |
| BioCyc | Methylglyoxal degradation III | |||
| Acetone degradation I (to methylglyoxal) | ||||
| KEGG Pathway | Pentose and glucuronate interconversions | |||
| Fructose and mannose metabolism | ||||
| Galactose metabolism | ||||
| Glycerolipid metabolism | ||||
| Metabolic pathways | ||||
| NetPath Pathway | IL1 Signaling Pathway | |||
| TGF_beta_Receptor Signaling Pathway | ||||
| Pathwhiz Pathway | Fructose and Mannose Degradation | |||
| Pyruvate Metabolism | ||||
| Pterine Biosynthesis | ||||
| Glycerolipid Metabolism | ||||
| Galactose Metabolism | ||||
| WikiPathways | Metapathway biotransformation | |||
| Polyol Pathway | ||||
| Metabolism of steroid hormones and vitamin D | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7418). | |||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000004) | |||
| REF 3 | The effects of zenarestat, an aldose reductase inhibitor, on minimal F-wave latency and nerve blood flow in streptozotocin-induced diabetic rats. Life Sci. 2001 Feb 9;68(12):1439-48. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.